Ann: Singapore Healthcare Day Presentation, page-59

NZ Trader , and others , keep reminding us what a catalyst ODD will be.

It's actually far bigger than that IMHO.
My logic below .. please let me know ( gently ), if I have this wrong.

Perhaps this snippet from a piece written by Matthew Baker from Blue Ocean Equities on the benefits of ODD designation brings clarity to the thinking.



"Off-Label" usage is legal for approved drugs for rare diseases.
When PharmAust gets ODD, it has been flagged by the FDA as drug with a possible therapy for a rare disease, MND/ALS.
When the Phase 2/3 trial is at 24 weeks, MPL may be fast tracked to approval.

Then MPL can prescribed for other neurodegenerative diseases.
MPL could also be prescribed for any condition where inducing autophagy could be beneficial, as the only SAFE, autophagy inducing drug on the market.
I believe over 80 conditions have been identified as being likely to benefit from enhanced autophagy.

MPL then has every change of being a mega blockbuster drug.

IMHO, share holders need to sit back and look at the big picture here.
Hold, and ignore the daily gyrations ... the gyrations will only become bigger as " the dark forces of the ASX " start appearing to wrestle your shares from you.

All IMO.
Please DYOR.